HIV/AIDS

What it is

HIV (human immunodeficiency virus) is a retrovirus that targets the immune system. Untreated, it progresses to AIDS (acquired immune deficiency syndrome), defined by severely depleted CD4 T-cell counts and opportunistic infections. Modern antiretroviral therapy has transformed HIV into a chronic manageable condition for most patients with consistent access to treatment.

Cachexia (severe wasting) and peripheral neuropathy remain common in advanced disease and in patients with treatment-related adverse effects.

Cannabis and cannabis-derived therapies

The 2017 NASEM consensus report identified moderate evidence for cannabis improving appetite and inducing weight gain in HIV/AIDS-associated wasting. Dronabinol (a synthetic THC) has been FDA-approved for AIDS-related anorexia since 1992.

NASEM identified limited evidence for symptomatic improvement in HIV-associated peripheral neuropathy from inhaled or oral cannabis.

HIV/AIDS is a qualifying condition under nearly every US state medical cannabis program. Patients should coordinate cannabis use with their HIV care team given potential pharmacokinetic interactions with antiretroviral drugs.

Wasting and appetite

HIV-associated wasting syndrome (defined as unintentional weight loss greater than 10% of baseline, often with chronic diarrhea, weakness, or fever lasting more than 30 days) was a defining complication of pre-ART AIDS. Modern combination antiretroviral therapy (ART) has substantially reduced wasting prevalence, but it persists in patients with late diagnosis, treatment failure, or inability to maintain consistent ART.

Cannabis effects on appetite are mediated through CB1 receptor activation in hypothalamic feeding circuits. The acute appetite-stimulating effect (the "munchies" effect of THC) translates clinically to:

• Increased caloric intake: documented in controlled trials of dronabinol and smoked cannabis in HIV-positive patients.
• Weight gain: moderate-effect magnitude in HIV-associated wasting (1-3 kg over 6-8 weeks in pivotal trials of dronabinol). Weight gain is primarily fat mass; effects on lean body mass are smaller.
• Symptomatic relief: improved sense of well-being and reduced nausea.

Dronabinol (Marinol) has carried an FDA-approved indication for AIDS-associated anorexia since 1992. The labeled dose is 2.5 mg orally twice daily, titrated to 20 mg/day in divided doses. The indication predates modern ART; clinical use has declined as wasting prevalence has fallen.

HIV-associated peripheral neuropathy

HIV-associated sensory neuropathy is one of the most common chronic complications of HIV infection, affecting roughly 30-50% of patients at some point in the disease course. Causes include direct HIV-related nerve damage and toxicity from older nucleoside reverse transcriptase inhibitors (stavudine, didanosine — now rarely used).

The 2017 NASEM finding of substantial evidence for cannabis in chronic pain in adults applies to HIV-associated peripheral neuropathy. Early-2000s controlled trials of smoked cannabis (Abrams et al., 2007; Ellis et al., 2009) demonstrated significant pain reduction relative to placebo in HIV-positive patients with painful sensory neuropathy. These were among the first controlled trials of inhaled cannabis for any medical indication in the United States.

Practical considerations:

• Smoked cannabis carries respiratory infection risk in immunocompromised patients; vaporization or oral preparations may be preferred.
• Standard neuropathic-pain therapy (gabapentin, pregabalin, duloxetine, tricyclics) remains first-line.
• Cannabis is typically adjunctive rather than monotherapy.

ART pharmacokinetic interactions

Cannabinoids are metabolized through CYP450 enzymes that also metabolize many antiretroviral drugs. Documented or theoretical interactions:

• Protease inhibitors (ritonavir-boosted regimens): ritonavir is a strong CYP3A4 inhibitor that elevates cannabinoid levels. Conversely, cannabinoids (particularly CBD) can affect PI levels through reciprocal CYP3A4 effects. Most clinically relevant interaction class.
• NNRTIs (efavirenz, nevirapine, etravirine): efavirenz induces CYP3A4 and may lower THC levels with regular use. Rilpivirine has narrower interaction profile.
• Integrase inhibitors (dolutegravir, bictegravir, raltegravir): generally fewer CYP-mediated interactions; modern preferred ART regimens.
• NRTIs (tenofovir, emtricitabine, abacavir, lamivudine): not significantly affected by cannabinoids.
• Boosters (ritonavir, cobicistat): both are potent CYP3A4 inhibitors with broad interaction profiles.

Patients on ritonavir- or cobicistat-boosted regimens should discuss cannabis use with their HIV care provider. Most modern ART regimens (INSTI-based) have a more favorable interaction profile.

Immunological considerations

HIV-positive patients are immunocompromised; cannabis-related immune effects deserve attention:

• Smoked cannabis: carries inherent respiratory infection risk and may elevate pneumonia risk in immunocompromised patients. Vaporization or oral preparations are generally preferred.
• Contaminated cannabis: mold (Aspergillus, Penicillium), bacterial contamination, or pesticide residues can be hazardous in immunocompromised hosts. Pharmaceutical-grade or rigorously tested medical-program products are preferred over informal-market sources.
• THC immune-modulation: preclinical data show THC has some immunosuppressive effects; clinical relevance in well-controlled HIV is unclear but worth monitoring in patients with CD4 counts below 200 cells/mm³.
• Co-occurring hepatitis C: cannabis interactions with direct-acting antivirals (DAAs) for HCV are mostly not clinically significant for short DAA courses.

Mood and adherence

HIV-positive patients have elevated rates of depression and anxiety relative to the general population. ART adherence is critical to viral suppression; any factor that affects adherence requires attention.

Cannabis effects on ART adherence are mixed in the literature:

• Some observational data suggest moderate cannabis use is associated with comparable or better adherence than non-use.
• Heavy daily cannabis use has been associated with adherence concerns in some cohorts.
• Cannabis use disorder is a distinct condition requiring intervention.

Mood-related cannabis effects are individual; THC-dominant preparations can exacerbate anxiety in some patients while improving mood in others.

Long-term considerations

HIV is now a chronic manageable condition for most patients with consistent ART access. Long-term cannabis use considerations apply:

• Cannabis use disorder, with rates approximating general adult population.
• Respiratory effects with chronic smoking (vaporization reduces).
• Cognitive effects of acute intoxication.
• Potential interactions with aging-related comorbidities (cardiovascular disease, metabolic syndrome) more prevalent in long-term HIV survivors.

Practical guidance

• Coordinate cannabis use with the HIV care team, particularly on PI- or cobicistat-boosted regimens.
• Disclose cannabis use to all prescribers.
• Pharmaceutical-grade or rigorously tested medical-program products are preferred over informal-market sources, especially for immunocompromised patients.
• Vaporization or oral preparations are generally preferred over smoking.
• Monitor for medication-adherence effects.

Related conditions

HIV-positive patients commonly experience cachexia, peripheral-neuropathy, chronic-pain, hepatitis-c (co-infection), nausea, anxiety-disorders, and ptsd. The mmjnow library covers each as separate conditions with overlapping clinical considerations.